📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
50 announcements match the current filters (relevance ≥ 5).
Gujarat Themis Biosyn to Acquire Sanofi's Global Anti-TB Portfolio for €158 Million
Gujarat Themis Biosyn Limited (GTBL) has announced a major asset acquisition of Sanofi's global Anti-TB and Anti-Infective portfolio for approximately €158 million. The deal includes 13 established brands, such as Rifampicin and Rifapentine, which generated ~€62 million in revenue in FY 2025. This acquisition provides GTBL immediate access to over 55 countries across Europe and the MEA region. The transaction is structured as an asset-light model, funded by a mix of debt and equity, and is expected to be EPS accretive while enabling forward integration into APIs and finished dosages.
Key Highlights
Acquisition of 13 established global brands from Sanofi for a total consideration of €158 million
Acquired portfolio reported revenue of ~€62 million for FY 2025 with healthy gross margins
Immediate global expansion into 55+ countries including regulated markets in Europe and MEA
Strategic shift to an integrated 'Intermediate-to-API-to-FDF' model using existing fermentation strengths
Portfolio includes WHO Essential Medicines and EU Critical Drugs, ensuring resilient long-term demand
👀 What to Watch
This is a transformative deal that significantly scales GTBL's revenue and global footprint; investors should monitor the specific debt-equity mix for funding and the impact on interest coverage. Watch for regulatory approvals and the timeline for the integration of these brands into GTBL's existing fermentation-based manufacturing platform.
GTBL to Acquire Sanofi's Global Anti-TB Portfolio for EURO 158 Million
Gujarat Themis Biosyn (GTBL) has signed an asset purchase agreement to acquire Sanofi's global anti-TB and anti-infective portfolio for EURO 158 million. The acquisition includes 13 branded generic products across 55+ countries, which generated approximately EURO 62 million in net sales in 2025. This asset-light deal involves brands and marketing authorizations without manufacturing facilities, allowing GTBL to forward-integrate its fermentation-based API capabilities. The transaction is expected to be EPS accretive and is slated to close by Q3FY27, funded via a mix of debt and equity.
Key Highlights
Acquisition of 13 branded generic products from Sanofi for a total consideration of EURO 158 million.
The acquired portfolio reported net sales of approximately EURO 62 million for the year ended 2025.
Asset-light expansion covering 55+ countries in Europe, Middle East, and Africa without transferring employees or plants.
Strategic forward integration to leverage GTBL's existing fermentation-based API manufacturing expertise.
Transaction expected to be EPS accretive and close by the end of Q3FY27 (December 2026).
👀 What to Watch
This is a transformational acquisition that significantly expands GTBL's global footprint and margin potential; investors should monitor the final debt-equity funding ratio. The move into branded generics marks a major shift towards higher-value forward integration.
Gujarat Themis Biosyn to Acquire Sanofi's Anti-TB Portfolio for Euro 158 Million
Gujarat Themis Biosyn Limited (GTBL) has entered into an Asset Purchase Agreement with Sanofi to acquire 13 established branded generic products in the anti-TB and anti-infective segments. The acquisition, valued at Euro 158 million, covers a portfolio with a presence in over 55 countries across Europe, the Middle East, and Africa. The acquired brands reported net sales of approximately Euro 62 million for FY2025. This strategic move enables GTBL to achieve forward integration by leveraging its existing fermentation-based API capabilities for finished dosage formulations.
Key Highlights
Acquisition of 13 branded generic products from Sanofi for a cash consideration of Euro 158 million.
The portfolio generated revenues of Euro 62 million in FY25 and Euro 67 million in FY24.
Asset-light expansion involving only marketing authorizations, brands, and dossiers without manufacturing facilities or employees.
Provides immediate access to regulated and semi-regulated markets in 55+ countries.
Expected completion of the transaction by December 2026, subject to regulatory and antitrust approvals.
👀 What to Watch
This is a transformative acquisition for GTBL that significantly expands its global footprint and revenue potential. Investors should monitor the company's funding plan for the Euro 158 million cash payment and the subsequent margin improvements from forward integration.
GUJTHEM Shareholders Approve Related Party Transactions and Director Re-appointment
Gujarat Themis Biosyn Limited (GUJTHEM) has successfully passed two key resolutions via postal ballot. The re-appointment of Mrs. Kirandeep Madan as an Independent Director received overwhelming support with 99.99% of votes in favour. However, the resolution for Material Related Party Transactions with Themis Medicare Limited saw significant resistance, passing with a narrow 52.56% majority among voting shareholders, while 47.44% voted against it. This high level of dissent on the RPT resolution indicates a segment of the minority shareholders has concerns regarding the company's dealings with its related entity.
Key Highlights
Special Resolution for re-appointment of Mrs. Kirandeep Madan passed with 99.99% majority.
Material Related Party Transactions (RPT) with Themis Medicare Limited approved with 52.56% votes in favour.
Significant dissent on the RPT resolution with 47.44% of polled votes (1,258,122 shares) against the proposal.
Total voter turnout for the RPT resolution was 2.43% of the total share capital, as promoters were interested parties.
Public institutions showed high resistance to the RPT, with 98.46% of their polled votes being 'against'.
👀 What to Watch
Investors should scrutinize the terms of the related party transactions with Themis Medicare Limited given the high institutional dissent. While the resolutions passed, the narrow margin on the RPT suggests a need for closer monitoring of corporate governance and transaction transparency.
GUJTHEM Seeks Approval for ₹50 Cr Related Party Transactions and Director Re-appointment
Gujarat Themis Biosyn Limited has issued a postal ballot notice to seek shareholder approval for two key resolutions. The first resolution is the re-appointment of Mrs. Kirandeep Madan as an Independent Director for a second five-year term starting May 2026. The second resolution seeks approval for material related party transactions with Themis Medicare Limited (TML) totaling up to ₹50 Crores for the financial year 2026-27. The voting period is scheduled from March 19, 2026, to April 17, 2026, with results expected by April 21, 2026.
Key Highlights
Proposed re-appointment of Mrs. Kirandeep Madan as Independent Director for a 5-year term until April 30, 2031.
Seeking approval for Material Related Party Transactions with Themis Medicare Limited (TML) worth up to ₹50 Crores.
The ₹50 Crores transaction limit is specifically for the upcoming Financial Year 2026-27.
Remote e-voting period runs from March 19, 2026, to April 17, 2026.
Transactions are intended to be conducted in the ordinary course of business and on an arm's length basis.
👀 What to Watch
Investors should review the terms of the related party transactions with Themis Medicare to ensure they align with the company's growth and margin objectives. No immediate action is required other than participating in the e-voting process if desired.
Gujarat Themis Biosyn Q3 Net Profit Dips 4% to ₹12.46 Cr; Appoints New CFO
Gujarat Themis Biosyn reported a 10.1% year-on-year increase in total income to ₹43.78 crore for Q3 FY26. However, net profit for the quarter declined by 3.9% to ₹12.46 crore, primarily due to a significant rise in depreciation and employee benefit expenses. The company also announced a management transition, with Krupesh Patel appointed as the new CFO effective April 1, 2026, as the current CFO moves to a plant-level accounting role. The 9-month net profit stands at ₹35.79 crore, slightly lower than the ₹36.77 crore recorded in the previous year.
Key Highlights
Total Income for Q3 FY26 rose to ₹4,378.45 Lakhs from ₹3,976.15 Lakhs in Q3 FY25.
Net Profit after tax decreased to ₹1,246.46 Lakhs compared to ₹1,297.23 Lakhs in the same quarter last year.
Depreciation and Amortization expenses more than doubled to ₹388.81 Lakhs from ₹156.33 Lakhs YoY.
Mr. Krupesh Patel, an MBA/CS/ICWA professional, is appointed as CFO effective April 1, 2026.
A one-time financial impact of ₹13.36 lakhs was recognized following the notification of new Labour Codes.
👀 What to Watch
Investors should monitor the company's ability to scale revenue to offset the rising depreciation costs associated with recent capital expenditures. The stock remains a hold as core operations show steady revenue growth despite temporary margin pressure.
GUJTHEM Q3 Revenue Up 10%, EBITDA Up 13%; New API Unit and 18.5 MW Power Plant Progressing
Gujarat Themis Biosyn reported a 9.74% YoY increase in Q3 FY26 revenue to ₹43.37 crore, supported by healthy demand and volume growth. EBITDA grew 12.93% to ₹22.06 crore with strong margins of 49.13%, although PAT declined slightly by 3.92% to ₹12.46 crore due to higher depreciation and interest from recent capex. The company is successfully transitioning toward forward integration, having completed validation batches in its new API block. Furthermore, a new 18.5 MW hybrid renewable power plant is being established to optimize long-term power costs and enhance sustainability.
Key Highlights
Q3 FY26 Revenue increased 9.74% YoY to ₹43.37 crore with EBITDA margins improving 139 bps to 49.13%.
Completed new fermentation facility and finished validation batches for the forward-integrated API production block.
Setting up a 18.5 MW Wind-Solar hybrid power plant for captive consumption to reduce grid dependence and costs.
R&D expenditure maintained at 3% of revenue for the 9-month period to drive new product development.
Net Block (Property, Plant & Equipment) increased significantly to ₹159.36 crore as major capex projects are capitalized.
👀 What to Watch
Investors should focus on the successful commercialization and ramp-up of the new API facility which marks a shift in the business model. While depreciation and interest costs may weigh on PAT in the short term, the forward integration and captive power project are strong long-term margin drivers.
Gujarat Themis Biosyn Q3 Profit at ₹12.46 Cr; Appoints Krupesh Patel as New CFO
Gujarat Themis Biosyn Limited reported a 10.1% YoY increase in total income to ₹43.78 crore for Q3 FY26. However, net profit saw a slight decline to ₹12.46 crore from ₹12.97 crore in the previous year's corresponding quarter, largely due to a significant rise in depreciation and employee expenses. The company also announced a strategic management transition, appointing Mr. Krupesh Patel as the new CFO effective April 1, 2026, as the current CFO moves to a plant-focused accounting role. Additionally, the board approved the re-appointment of Ms. Kirandeep Madan as an Independent Director for a second five-year term.
Key Highlights
Total Income for Q3 FY26 rose to ₹4,378.45 Lakhs compared to ₹3,976.15 Lakhs in Q3 FY25.
Net Profit after tax decreased by 3.9% YoY to ₹1,246.46 Lakhs due to higher operational costs.
Depreciation and Amortisation expenses more than doubled to ₹388.81 Lakhs from ₹156.33 Lakhs YoY.
Mr. Krupesh Patel appointed as CFO starting April 2026, bringing 15 years of experience from Tata Advanced Systems and Lupin.
Current CFO Mr. Bhavik Shah to transition to Senior Accounts Manager to focus on plant-related accounting and ongoing projects.
👀 What to Watch
Investors should note the margin pressure caused by rising depreciation and employee costs despite steady revenue growth. The transition in the finance department appears to be a planned internal restructuring to strengthen plant-level operations and corporate finance separately.
Gujarat Themis Biosyn Q3 Revenue Up 10% YoY; Appoints Krupesh Patel as New CFO
Gujarat Themis Biosyn reported a 10.1% YoY increase in total income for Q3 FY26, reaching ₹4,378.45 lakhs. Despite the revenue growth, net profit slightly declined by 3.9% YoY to ₹1,246.46 lakhs, impacted by a significant rise in depreciation and employee costs. The company announced a management transition with Mr. Krupesh Patel taking over as CFO from April 1, 2026, as the incumbent moves to a plant-level role. Additionally, Ms. Kirandeep Madan was re-appointed as an Independent Director for a second five-year term.
Key Highlights
Total income for Q3 FY26 grew to ₹4,378.45 lakhs from ₹3,976.15 lakhs in Q3 FY25.
Net profit for the quarter stood at ₹1,246.46 lakhs, a marginal decrease from ₹1,297.23 lakhs YoY.
Depreciation and Amortization expenses more than doubled to ₹388.81 lakhs compared to ₹156.33 lakhs in the previous year.
Mr. Krupesh Patel appointed as CFO effective April 1, 2026, bringing 15 years of experience from firms like Tata Advanced Systems and Wockhardt.
Nine-month net profit for FY26 reached ₹3,579.03 lakhs compared to ₹3,677.35 lakhs in the corresponding period last year.
👀 What to Watch
Investors should monitor if the increased depreciation, likely stemming from recent capital expenditure, leads to higher production capacity and revenue in coming quarters. The management transition appears orderly, but the slight dip in profitability despite revenue growth warrants a cautious watch on operating margins.
Gujarat Themis Biosyn Q3 FY26: Revenue Up 9.7% YoY to ₹43.37 Cr, Net Profit Dips to ₹12.46 Cr
Gujarat Themis Biosyn Limited reported a 9.7% YoY increase in revenue from operations, reaching ₹43.37 crore for the quarter ended December 31, 2025. Despite the revenue growth, net profit declined to ₹12.46 crore from ₹12.97 crore in the same period last year, primarily due to a sharp rise in depreciation and employee benefit expenses. The company also announced a leadership transition with Mr. Krupesh Patel appointed as the new CFO effective April 1, 2026. For the nine-month period, the company's net profit stands at ₹35.79 crore, slightly lower than the ₹36.77 crore recorded in the previous year.
Key Highlights
Revenue from operations grew 9.7% YoY to ₹43.37 crore compared to ₹39.52 crore in Q3 FY25.
Net profit after tax stood at ₹12.46 crore, down 3.9% YoY and 12.6% QoQ.
Depreciation and Amortization expenses surged to ₹3.89 crore from ₹1.56 crore in the year-ago quarter.
Employee benefit expenses increased significantly to ₹4.76 crore from ₹3.02 crore YoY.
Mr. Krupesh Patel appointed as CFO effective April 1, 2026, succeeding Mr. Bhavik Shah who is transitioning to a different role.
👀 What to Watch
Investors should monitor the margin pressure resulting from increased depreciation and employee costs despite steady revenue growth. The transition in the CFO role and the impact of ongoing projects on future profitability remain key areas to watch.
